• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Turkey·Healthcare·ECILC.IS
Share

EIS Eczacibasi Ilac, Sinai ve Finansal Yatirimlar Sanayi ve Ticaret A.S. Stocks

TRY 76.5Last Updated 27.08.2026

Issuer Rating

4/7
Performance

Modest

Risk

Limited

Recommendation

Hold

Market Cap

TRY 1.09B

TRY 76.5
Key Takeaways

Risk factor

Resilient to price shocks

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

EIS Eczacibasi Ilaç, Sinai ve Finansal Yatirimlar Sanayi ve Ticaret A.S. is a Turkish enterprise, operating predominantly in the health and real estate development sectors through its various subsidiaries. Its Health division is responsible for the production and distribution of pharmaceutical goods for both human and veterinary applications. Concurrently, the Real Estate Development segment is engaged in property creation and offers consultancy pertaining to land development and project oversight. This company, established in Istanbul, Turkey, in 1951, functions as a subsidiary of Eczacibasi Holding A.S.

Company Valuation

Greatly overvalued
1/7

Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. In particular, the stock is 'expensive' on EV/EBITDA, overvalued on P/F

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

28.08.2026 17:18

"Hot Potato": Why Burry is Bearish on Build-A-Bear Stock

28.08.2026 16:45

Wendy's stock plummeted after Nelson Peltz's fund decided not to buy the company

28.08.2026 16:15

Gold mining stocks outperformed chipmakers' stocks in August. Who's in the black?

28.08.2026 15:50

Morgan Stanley saw a "unique opportunity" in SpaceX shares after their plunge

28.08.2026 15:39

Morning in New York: The Jackson Hole Mountains Stand in the Way of the AI Rally

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026